8-K
filed May 17, 2022, 7:59 PM ET
ticker APRE
CIK 0001781983
M&A
confidence high
sentiment neutral
materiality 0.75
Aprea completes acquisition of Atrin; appoints Oren Gilad as CEO, new directors
Aprea Therapeutics, Inc.
- Issued 1,117,394 common shares and 2,949,630 Series A Preferred (each convertible into 10 common) to Atrin securityholders.
- Certain stockholders agreed to 180-day lock-up on sale of shares received in merger.
- CVRs entitle Aprea legacy holders to cash from disposition of mutant p53 assets within 2 years.
- Oren Gilad appointed President, to become CEO; Christian Schade to stay as Executive Chairman for 6 months.
- Aprea notified Nasdaq of audit committee vacancy due to director resignation; intends to regain compliance.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Fouad Namouni resigned as Director at Aprea Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
Fouad Namouni and Michael A. Kelly resigned from the Board as Class II and Class III directors, respectively, and any respective committee of the Board to which they were members, effective at the Second Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Rif Pamukcu was appointed as Director at Aprea Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Michael Grissinger and Rif Pamukcu were appointed as Class II directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Grissinger was appointed as Director at Aprea Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Michael Grissinger and Rif Pamukcu were appointed as Class II directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael A. Kelly resigned as Director at Aprea Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
Fouad Namouni and Michael A. Kelly resigned from the Board as Class II and Class III directors, respectively, and any respective committee of the Board to which they were members, effective at the Second Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Greg Korbel was appointed as Chief Operating Officer at Aprea Therapeutics, Inc..
- Action
- appointed
- Role
- Chief Operating Officer
Exact text from the filing
the appointment of Greg Korbel to the position of the Chief Operating Officer of Aprea
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Oren Gilad was appointed as Chief Executive Officer at Aprea Therapeutics, Inc..
- Action
- appointed
- Role
- Chief Executive Officer
Exact text from the filing
Effective as of the conclusion of the Stockholders’ Meeting, Dr. Gilad will be appointed to the position of Chief Executive Officer of Aprea, to fill the vacancy created by Christian S. Schade’s resignation as Chief Executive Officer of Aprea
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Christian S. Schade resigned as Chief Executive Officer at Aprea Therapeutics, Inc..
- Action
- resigned
- Role
- Chief Executive Officer
Exact text from the filing
Effective as of the conclusion of the Stockholders’ Meeting, Christian S. Schade will resign as Chief Executive Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Oren Gilad was appointed as President at Aprea Therapeutics, Inc..
- Action
- appointed
- Role
- President
Exact text from the filing
the appointment of Oren Gilad, Ph.D. to the position of the President of Aprea
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Marc Duey was appointed as Director at Aprea Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Marc Duey was appointed as a Class I director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Oren Gilad was appointed as Director at Aprea Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Dr. Gilad was appointed as a Class III director
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.